MEM, also known as 2,5-dimethoxy-4-ethoxyamphetamine or as TMA2-4-EtO, is a psychedelic drug of the phenethylamine, amphetamine, and DOx families related to TMA-2. It is the analogue of TMA-2 in which the methoxy group at the 4 position has been replaced with an ethoxy group. The drug was first described in the scientific literature by Alexander Shulgin by 1968.
In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists MEM's dose as 20 to 50mg orally and its duration as 10 to 14hours. Its effects have been reported to include color enhancement, visual phenomena, and pattern movement, among others.
MEM is a serotonergic psychedelic and acts as a selective serotonin 5-HT<sub>2</sub> receptor agonist. It is specifically a full agonist of the serotonin 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors and to a lesser extent is a partial to full agonist of the serotonin 5-HT<sub>2B</sub> receptor. The psychedelic effects of MEM are thought to be mediated by serotonin 5-HT<sub>2A</sub> receptor activation.
MEM, also known as 2,5-dimethoxy-4-ethoxyamphetamine, is a phenethylamine, amphetamine, and DOx derivative. It is the analogue and derivative of 2,4,5-trimethoxyamphetamine (TMA-2) in which a 4-ethoxy group is present instead of a 4-methoxy group.
The chemical synthesis of MEM has been described.
A variety of derivatives of MEM have been developed and studied, not only by Alexander Shulgin but also by for instance Daniel Trachsel and colleagues. These include MPM, MIPM, MALM, MBM, MAM, MMALM, MFEM, MDFEM, and MTFEM, among others.
MEM was first synthesized by Alexander Shulgin. It was first described by him in the scientific literature by 1968. Subsequently, Shulgin described MEM in greater detail in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).
MEM is a controlled substance in Canada.
MEM is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.